查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1601251

RNA干扰技术市场：按类型、治疗方法、应用分类 - 2025-2030 年全球预测

RNA Interference Technology Market by Type (dsRNA, miRNA, siRNA), Therapeutics (Autoimmune Hepatitis, Hepatitis B and C, Neurological Disorders), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年RNA干扰技术市场规模为329.2亿美元，预计2024年将达392.5亿美元，复合年增长率为22.38%，2030年将达1354亿美元。

RNA干扰（RNAi）技术是分子生物学中的革命性工具，能够定序特定基因，为研究基因功能和开发新的治疗策略提供了强大的手段。其范围涵盖广泛的领域，包括基础研究、药物发现和治疗应用，主要关注遗传性疾病和后天性疾病。 RNAi 的需求在于其精确靶向致病基因的独特能力，这为癌症、病毒感染疾病、遗传性疾病等的个人化医疗和治疗带来了希望。最终用途广泛，包括製药公司、生技公司和学术研究机构。

主要市场统计
基准年[2023] 329.2亿美元
预测年份 [2024] 392.5亿美元
预测年份 [2030] 1,354亿美元
复合年增长率（%） 22.38%

RNAi 技术的市场成长受到技术进步、慢性病盛行率增加以及对个人化医疗日益增长的兴趣的显着影响。此外，对 RNAi 研发的大量投资以及学术机构和生物技术公司之间的合作正在为技术创新打开新的大门。递送方法的最新趋势以及有效和选择性 siRNA 的开发为临床应用提供了巨大的机会。虽然北美目前凭藉强大的医疗基础设施和研究活动处于领先地位，但由于医疗保健投资的增加和政府对基因研究的资助的增加，预计亚太地区将出现显着增长。

然而，该市场面临一些限制，包括 RNAi 分子向细胞质的递送挑战、潜在的脱靶效应以及提高生物环境稳定性的需要。此外，监管障碍和高昂的开发成本仍然是市场成长和渗透的主要挑战。专注于增强递送系统、提高标靶特异性以及利用奈米粒子实现更安全、更有效的 RNAi 递送的创新是有前景的研究和开发领域。该公司正在投资将 RNAi 与 CRISPR 等其他基因编辑技术相结合，以扩大治疗应用，并利用与学术研究机构的合作来加速这个充满活力的市场的创新和采用。

市场动态：揭示快速发展的RNA干扰技术市场的关键市场洞察

RNA干扰技术市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球遗传疾病和慢性病盛行率上升
    • 扩大RNAi技术在药物发现与药物开发的应用
    • 对分子诊断的需求不断增长
  • 市场限制因素
    • FDA 对 RNAi 治疗的严格规定
  • 市场机会
    • 奈米技术和癌症领域的持续研究和开发
    • 正在开发的尖端 RNAi 疗法
  • 市场挑战
    • RNA干扰治疗实施中的担忧

波特五力：驾驭RNA干扰科技市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解RNA干扰技术市场的外部影响

外部宏观环境因素在塑造RNA干扰技术市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解RNA干扰技术市场的竞争状况

RNA干扰技术市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵RNA干扰技术市场供应商绩效评估

FPNV定位矩阵是评估RNA干扰技术市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球遗传疾病和慢性病的增加
      • 扩大RNAi技术在药物发现与开发的应用
      • 分子诊断的需求不断增加
    • 抑制因素
      • FDA 对 RNAi 治疗的严格规定
    • 机会
      • 奈米技术和癌症领域的持续研究和开发
      • 正在开发的尖端 RNAi 疗法
    • 任务
      • 对RNA干扰疗法实施的担忧
  • 市场区隔分析
    • 类型：利用siRNA进行标靶基因治疗，治疗多种疾病
    • 应用：快速采用RNA干扰技术进行药物发现与开发
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境
  • 客户客製化

第六章RNA干扰技术市场：依类型

  • 双链RNA
  • 微型RNA
  • siRNA

第七章RNA干扰技术市场治疗

  • 自体免疫肝炎
  • 乙型肝炎及丙型肝炎
  • 神经系统疾病
  • 肿瘤学
  • 呼吸系统疾病

第八章RNA干扰技术市场：依应用分类

  • 药物发现与开发
  • 治疗药物

第九章 美洲RNA干扰技术市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太RNA干扰技术市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东、非洲RNA干扰技术市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Switch Therapeutics 融资 5,200 万美元用于开发首个 RNAi 技术
    • Alnylam Pharmaceuticals 和 Medison Pharma 宣布将合作范围扩大到多地域伙伴关係，以实现 RNAi 疗法的商业化

公司名单

  • Gradalis, Inc.
  • Arcturus Therapeutics Holdings Inc.
  • Merck KGaA
  • NeuBase Therapeutics, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Novartis AG
  • Nutcracker Therapeutics, Inc.
  • Bioneer Corporation
  • Ionis Pharmaceuticals, Inc.
  • Arbutus Biopharma Corporation
  • AMSBIO
  • Atalanta Therapeutics
  • Phio Pharmaceuticals Corp.
  • Thermo Fisher Scientific Inc.
  • Sanofi SA
  • AstraZeneca PLC
  • Dicerna Pharmaceuticals, Inc.
  • Sirnaomics, Inc.
  • ProQR Therapeutics NV
  • Silence Therapeutics PLC
  • CureVac NV
  • Alnylam Pharmaceuticals, Inc.
  • Gotham Therapeutics Corp.
Product Code: MRR-0375F3EAA810

The RNA Interference Technology Market was valued at USD 32.92 billion in 2023, expected to reach USD 39.25 billion in 2024, and is projected to grow at a CAGR of 22.38%, to USD 135.40 billion by 2030.

RNA interference (RNAi) technology is a revolutionary tool in molecular biology that enables the silencing of specific genes, thus providing a powerful means for studying gene function and developing novel therapeutic strategies. Its scope extends across multiple dimensions, including basic research, drug discovery, and therapeutic application, primarily focusing on genetic and acquired diseases. The necessity of RNAi lies in its unique ability to precisely target disease-causing genes, thereby offering promise in personalized medicine and treatment of conditions like cancer, viral infections, and genetic disorders. The tight end-use scope involves pharmaceuticals, biotechnology companies, and academic research institutions.

KEY MARKET STATISTICS
Base Year [2023] USD 32.92 billion
Estimated Year [2024] USD 39.25 billion
Forecast Year [2030] USD 135.40 billion
CAGR (%) 22.38%

Market growth for RNAi technology is heavily influenced by technological advancements, increasing incidences of chronic diseases, and the expanding interest in personalized medicine. Additionally, substantial investments in RNAi research and development, along with collaborations between academic institutions and biotech firms, are opening new doors for innovation. Recent advancements in delivery methods and the development of potent and selective siRNAs present significant opportunities in clinical applications. The North American region is currently leading due to robust healthcare infrastructure and research activity, yet Asia-Pacific is expected to witness substantial growth due to rising healthcare investments and increased government funding for genetic research.

However, the market faces several limitations, such as delivery challenges of RNAi molecules into the cell cytoplasm, potential off-target effects, and the necessity for improved stability in biological settings. Furthermore, regulatory hurdles and high development costs remain significant challenges to market growth and widespread adoption. Innovations focusing on enhanced delivery systems, improved target specificity, and utilizing nanoparticles for safer and more effective RNAi delivery are promising areas for research and development. Companies should invest in merging RNAi with other gene-editing technologies like CRISPR to expand therapeutic applications and leverage partnerships with academic and research institutions to accelerate innovation and adoption in this dynamic market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving RNA Interference Technology Market

The RNA Interference Technology Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising Prevalence of Genetic and Chronic Disorders Globally
    • Increasing Application of RNAi Technology in Drug Discovery & Development
    • Growing Need for Molecular Diagnostics
  • Market Restraints
    • Stringent FDA Regulations Regarding RNAi Therapies
  • Market Opportunities
    • Ongoing Research and Development in the Field of Nanotechnology and Cancer
    • State-of-the-art RNAi Therapies in Development
  • Market Challenges
    • Concerns in Delivery of RNA-Interference Therapies

Porter's Five Forces: A Strategic Tool for Navigating the RNA Interference Technology Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the RNA Interference Technology Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the RNA Interference Technology Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the RNA Interference Technology Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the RNA Interference Technology Market

A detailed market share analysis in the RNA Interference Technology Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the RNA Interference Technology Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the RNA Interference Technology Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the RNA Interference Technology Market, highlighting leading vendors and their innovative profiles. These include Gradalis, Inc., Arcturus Therapeutics Holdings Inc., Merck KGaA, NeuBase Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Novartis AG, Nutcracker Therapeutics, Inc., Bioneer Corporation, Ionis Pharmaceuticals, Inc., Arbutus Biopharma Corporation, AMSBIO, Atalanta Therapeutics, Phio Pharmaceuticals Corp., Thermo Fisher Scientific Inc., Sanofi S.A., AstraZeneca PLC, Dicerna Pharmaceuticals, Inc., Sirnaomics, Inc., ProQR Therapeutics N.V., Silence Therapeutics PLC, CureVac N.V., Alnylam Pharmaceuticals, Inc., and Gotham Therapeutics Corp..

Market Segmentation & Coverage

This research report categorizes the RNA Interference Technology Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across dsRNA, miRNA, and siRNA.
  • Based on Therapeutics, market is studied across Autoimmune Hepatitis, Hepatitis B and C, Neurological Disorders, Oncology, and Respiratory Disorders.
  • Based on Application, market is studied across Drug Discovery and Development and Therapeutics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising Prevalence of Genetic and Chronic Disorders Globally
      • 5.1.1.2. Increasing Application of RNAi Technology in Drug Discovery & Development
      • 5.1.1.3. Growing Need for Molecular Diagnostics
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent FDA Regulations Regarding RNAi Therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing Research and Development in the Field of Nanotechnology and Cancer
      • 5.1.3.2. State-of-the-art RNAi Therapies in Development
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns in Delivery of RNA-Interference Therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: siRNA's use for targeted gene therapy for treating a multitude of diseases
    • 5.2.2. Application: Exponential adoption of RNA interference technology for dru discovery & development
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. RNA Interference Technology Market, by Type

  • 6.1. Introduction
  • 6.2. dsRNA
  • 6.3. miRNA
  • 6.4. siRNA

7. RNA Interference Technology Market, by Therapeutics

  • 7.1. Introduction
  • 7.2. Autoimmune Hepatitis
  • 7.3. Hepatitis B and C
  • 7.4. Neurological Disorders
  • 7.5. Oncology
  • 7.6. Respiratory Disorders

8. RNA Interference Technology Market, by Application

  • 8.1. Introduction
  • 8.2. Drug Discovery and Development
  • 8.3. Therapeutics

9. Americas RNA Interference Technology Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific RNA Interference Technology Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa RNA Interference Technology Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Switch Therapeutics Launches with USD 52 Million to Advance First-of-its-Kind RNAi Technology
    • 12.3.2. Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics

Companies Mentioned

  • 1. Gradalis, Inc.
  • 2. Arcturus Therapeutics Holdings Inc.
  • 3. Merck KGaA
  • 4. NeuBase Therapeutics, Inc.
  • 5. Arrowhead Pharmaceuticals, Inc.
  • 6. Novartis AG
  • 7. Nutcracker Therapeutics, Inc.
  • 8. Bioneer Corporation
  • 9. Ionis Pharmaceuticals, Inc.
  • 10. Arbutus Biopharma Corporation
  • 11. AMSBIO
  • 12. Atalanta Therapeutics
  • 13. Phio Pharmaceuticals Corp.
  • 14. Thermo Fisher Scientific Inc.
  • 15. Sanofi S.A.
  • 16. AstraZeneca PLC
  • 17. Dicerna Pharmaceuticals, Inc.
  • 18. Sirnaomics, Inc.
  • 19. ProQR Therapeutics N.V.
  • 20. Silence Therapeutics PLC
  • 21. CureVac N.V.
  • 22. Alnylam Pharmaceuticals, Inc.
  • 23. Gotham Therapeutics Corp.

LIST OF FIGURES

  • FIGURE 1. RNA INTERFERENCE TECHNOLOGY MARKET RESEARCH PROCESS
  • FIGURE 2. RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. RNA INTERFERENCE TECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. RNA INTERFERENCE TECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RNA INTERFERENCE TECHNOLOGY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RNA INTERFERENCE TECHNOLOGY MARKET DYNAMICS
  • TABLE 7. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DSRNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MIRNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SIRNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY AUTOIMMUNE HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY HEPATITIS B AND C, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. RNA INTERFERENCE TECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. RNA INTERFERENCE TECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2023